Identification and validation of novel pharmaceutical drug targets for cardiovascular disease

From 2013-10-01 to 2017-09-30, closed project | CARTARDIS Website

Project details

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>Topic(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 7 980 425</td>
<td>HEALTH.2013.2.4.2.1 - Discovery research to reveal novel targets for cardiovascular disease treatment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EU contribution:</th>
<th>Call for proposal:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 5 973 521</td>
<td>FP7-HEALTH-2013-INNOVATION-1 See other projects for this call</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coordinated in:</th>
<th>Funding scheme:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Netherlands</td>
<td>CP-FP - Small or medium-scale focused research project</td>
</tr>
</tbody>
</table>

Objective

"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of €192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The introduction of statins has reduced morbidity and mortality of atherosclerosis by 30%, however a large untreatable residual cardiovascular risk remains even in cohorts of treated patients. Currently, many targets for CVD treatment have been selected based on mechanism of action and inference of functions in cellular models to clinical systems, and lack the rigorous clinical validation needed to maximize the chance for successful clinical drug development. Consequently, new drugs that modulate the activity of such targets fail later in clinical development by lack of efficacy or induction of safety liabilities due to off-target effects. To increase the success rate for clinical development of novel therapies in CVD, we will follow an innovative approach by using: 1. Independent and large-scale population studies from which novel targets with strong correlation to clinical phenotypes are deduced; 2. Translational disease-mimicking models (cellular and animal) to validate novel drug targets; 3. High quality human biobanks to confirm the molecular relevance of targets in diseased cardiovascular tissues; 4. A stringent pharmaceutical drug discovery process for prioritization of drugable targets. An important concept, in line with the changed pharmaceutical business model, is that these steps can best be executed by a functional network of clinical academic centers and specialized SMEs under the guidance of established and experienced drug discovery researchers from industry that brings together the right components and expertise to execute such a modular target discovery process."

Related information

<table>
<thead>
<tr>
<th>Report Summaries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final Report Summary - CARTARDIS (Identification and validation of novel pharmaceutical drug targets for cardiovascular disease)</td>
</tr>
</tbody>
</table>
Coordinator

NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO
ANNA VAN BUERENPLEIN 1
2595 DA DEN HAAG
Netherlands
EU contribution: EUR 939 353

Activity type: Research Organisations

Administrative contact: Alain Van Gool
Tel.: +31 611783031
Fax: +31 888660609
Contact the organisation

Participants

HELMHOLTZ ZENTRUM MUEENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT
UND UMWELT GMBH
INGOLSTADTER LANDSTRASSE 1
85764 NEUHERBERG
Germany
EU contribution: EUR 700 083

Activity type: Research Organisations

Administrative contact: Juergen Ertel
Tel.: +49 89 3187 3022
Fax: +49 89 3187 3866
Contact the organisation

KAROLINSKA INSTITUTET
Nobels Vag 5
17177 STOCKHOLM
Sweden
EU contribution: EUR 598 000

Activity type: Higher or Secondary Education Establishments

Administrative contact: Kindaker Therese
Tel.: +46851773122
Contact the organisation
ASTRAZENECA AB  
Vastra Maelarhamnen  
151 85 SODOERTAELJE  
Sweden  
EU contribution: EUR 250 112

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Eva Hurt-Camejo  
Tel.: +46 317762967

Contact the organisation

HJARTAVERND SES  
HOLTASMAR 1  
201 KOPAVOGUR  
Iceland  
EU contribution: EUR 499 499

Activity type: Research Organisations

Administrative contact: Vilmundur Gudnason  
Tel.: +354 5351800

Contact the organisation

ACADEMISCH ZIEKENHUIS LEIDEN  
ALBINUSDREEF 2  
2333 ZA LEIDEN  
Netherlands  
EU contribution: EUR 300 720

Activity type: Higher or Secondary Education Establishments

Administrative contact: Jan Lindeman  
Tel.: +31 715263968

Contact the organisation

CARDIOGENX BV  
LICHTENAUERLAAN 30  
3006AG ROTTERDAM  
Netherlands  
EU contribution: EUR 701 024

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Dharminder Chahal  
Tel.: +31 614613416

Contact the organisation
POLYGENE AG
RIEDMATTSTRASSE 9
8153 RÜMLANG
Switzerland
EU contribution: EUR 697 930

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Doron Shmerling
Tel.: +41 448286382
Fax: +41 448286381
Contact the organisation

BIONEER A/S
KOGLE ALLE 2
2970 HOERSHOLM
Denmark
EU contribution: EUR 296 000

Activity type: Research Organisations

Administrative contact: Kim Holmström
Tel.: +45 45160444
Contact the organisation

IMABIOTECH SAS
885 AV EUGENE AVINEE
59120 LOOS
France
EU contribution: EUR 296 000

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Jonathan Stauber
Tel.: +33 632940351
Contact the organisation

MORPHISTO EVOLUTIONSFORSCHUNG UND ANWENDUNG GMBH
WEISMULLERSTRASSE 45
60314 FRANKFURT AM MAIN
Germany
EU contribution: EUR 295 000

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Michael Gudo
Tel.: +49 69400301962
Contact the organisation
UMEA UNIVERSITET
UNIVERSITETOMRADET
901 87 UMEA
Sweden
See on map

Activity type: Higher or Secondary Education Establishments

Administrative contact: Stefan Nilsson
Tel.: +46 705781768
Contact the organisation

MAARTEN DANIEL SOLLEWIJN GELPKE
SHERBROOKE WAY 64
KT4 8BP WORCESTER PARK SURREY
United Kingdom

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Maarten Sollewijn Gelpke
Tel.: +44 7765121280
Contact the organisation

Subjects

Life Sciences

Last updated on 2015-06-01
Retrieved on 2019-07-24

© European Union, 2019